Phone: +44 141 899 0081

Archive

Home / Tag: Patient Access

Want to know more about our PRIME & EAMS / PIM experience? Meet us at the 2017 DIA EuroMeeting in Glasgow, 29 – 31 March 2017

With the increasing acknowledgement of the need to develop an overarching scheme to enhance support for sponsors developing medicines, tackling unmet medical needs to ensure timely access to beneficial therapies, the EMA launched the PRIME scheme in March 2016. This

Kinesys secures another Promising Innovative Medicine (PIM) Designation from the UK MHRA

Kinesys Consulting last month secured another PIM designation, this time for a new oncology product, on behalf of a US partner. The product, successfully designated as a Promising Innovative Medicine (PIM) by the Medicines and Healthcare Products Regulatory Agency (MHRA), is being developed for the treatment of

Kinesys Consulting secures its first PIM designation from UK MHRA under the EAMS – Early Access to Medicines Scheme

Kinesys Consulting has secured its first PIM designation, for a novel oncology supportive care product, on behalf of a US partner. The product, designated as a Promising Innovative Medicine (PIM) by the Medicines and Healthcare Products Regulatory Agency (MHRA), is being developed for

Adaptive Pathways, Biosimilars, Rare Diseases – ISPOR 19th Annual European Congress – 29 Oct-2 Nov 2016, Vienna, Austria

Adaptive Pathways and Patient AccessAn issue panel entitled Adaptive Pathways and Patient Access: Pushing Payer Boundaries or Facilitating New Payment Models? was held and moderated by Jacoline Bouvy, Scientific Adviser, National Institute for Health and Care Excellence (NICE), London, UK. Jacoline